Salarius Pharmaceuticals Regains Compliance with Nasdaq
Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) has reached a significant milestone by regaining compliance with all Nasdaq listing requirements. This achievement comes after the company received notification on October 10, 2025, from the Nasdaq Stock Market LLC, confirming compliance with Listing Rule 5550(b)(1), which covers the Equity Standard Requirement.
Progress in Merger with Decoy Therapeutics
Mark J. Rosenblum, acting CEO and CFO of Salarius, expressed optimism about their future, stating, "Salarius is now fully compliant with all Nasdaq listing requirements, marking another critical step in our planned merger with Decoy Therapeutics." This merger is poised to combine Salarius' deep expertise in oncology with Decoy's innovative therapeutic approaches.
Merger Agreement Details
On January 13, 2025, Salarius announced a definitive merger agreement with Decoy Therapeutics, Inc., a biotech company specializing in peptide conjugate therapeutics. This exciting venture aims to push forward advancements in the treatment of serious diseases, particularly targeting unmet medical needs in the fields of respiratory infectious diseases and gastrointestinal oncology.
Mandatory Monitoring and Future Expectations
As part of the compliance regaining process, Nasdaq also informed Salarius of a one-year Mandatory Panel Monitor period starting from the notification date. This monitoring is essential to ensure that Salarius maintains its compliance status. If the company fails to comply during this period, a delisting determination may follow, although Salarius retains the right to appeal such a decision.
Innovative Therapeutic Development
The planned merger with Decoy will enhance Salarius' pipeline, particularly through Decoy’s IMP3ACTTM platform, designed for the rapid creation of new peptide conjugate therapeutics. The integrated efforts will also focus on incorporating Salarius’ existing drug candidate, SP-3164, which holds promise as a novel treatment for cancer.
Leadership and Strategic Direction
The newly formed company from the merger will be helmed by Decoy’s Co-founders, including CEO Frederick "Rick" Pierce and Chief Scientific Officer Barbara Hibner. The leadership team is poised to guide the company toward advancing its pipeline and achieving significant technological and therapeutic breakthroughs.
Next Steps for Decoy Therapeutics
In the coming year, Decoy expects to highlight its lead asset, a pan-coronavirus antiviral, by filing an Investigational New Drug (IND) application with the FDA. This application is anticipated to pave the way for further innovations in the treatment of various viral infections, while also continuing work on therapeutics for GI cancers.
Collaboration with MD Anderson
Research concerning Salarius’ innovative compound, seclidemstat, is ongoing through an investigator-initiated Phase 1/2 clinical trial at MD Anderson Cancer Center. This trial focuses on delivering treatment options for patients suffering from myelodysplastic syndrome and chronic myelomonocytic leukemia who often have limited choices.
About Salarius Pharmaceuticals
Salarius Pharmaceuticals is a clinical-stage biopharmaceutical company committed to developing new treatment options for cancer patients. With its lead candidate, seclidemstat, undergoing pivotal studies, Salarius strives to address significant treatment gaps in hematologic cancers. Additionally, the company supports innovation through its second candidate, SP-3164, which is entering into critical stages of development.
About Decoy Therapeutics
Operating at the forefront of biotechnology, Decoy Therapeutics is leveraging advanced technology including machine learning, to develop peptide-based drug candidates. Focused on tackling pressing health challenges related to respiratory viruses and GI cancers, Decoy is well-positioned for future breakthroughs in therapeutic interventions.
Frequently Asked Questions
What does it mean for Salarius to regain Nasdaq compliance?
Regaining Nasdaq compliance means that Salarius is meeting all necessary financial and organizational standards required for public listing, allowing it to continue trading on the exchange.
What is the significance of the merger with Decoy Therapeutics?
The merger is expected to combine Salarius' expertise in oncology with Decoy's innovative therapies, enhancing their capacity to address unmet medical needs in serious diseases.
How will the monitoring period affect Salarius?
The one-year monitoring period will involve scrutiny of the company’s compliance status. Should they falter, it may lead to further evaluations and potential delisting procedures.
What is the pipeline focus of Decoy Therapeutics?
Decoy Therapeutics focuses on developing peptide conjugate therapeutics, especially in areas of respiratory infectious diseases and GI oncology, aiming to deliver cutting-edge solutions.
Where can I find more information about Salarius Pharmaceuticals?
Detailed information about Salarius Pharmaceuticals and its clinical developments can be found on their official website at www.salariuspharma.com.
